Biotech Startups

XS Innovations develops medical devices for vascular access in hemodialysis patients. The company is led by clinical and engineering experts addressing kidney disease treatment.

1 investor

Xtant Medical is a tissue bank and developer of orthobiologics and spinal fixation systems, with vertically integrated operations from donor tissue recovery to distribution. It provides surgeons with biologic grafts and cervical, thoracolumbar, and interbody spinal implant systems for complex, deformity, and degenerative procedures.

1 investor

1 investor

Xyall operates in medical technology and molecular diagnostics, leveraging expertise in digital pathology and health innovation to scale diagnostic solutions.

1 investor

XYLYX develops transplantation technologies using regenerative medicine, bioengineering, and translational science to expand access to organ transplantation. The company works with surgeons, physicians, and regenerative medicine experts to advance tissue engineering and clinical innovation for transplant applications.

1 investor

Yanyin Tech develops an AI agent platform for biomedical research and drug discovery, offering a suite of tools including bioinformatics and laboratory collaboration software for pharmaceutical companies, research institutions, and universities.

1 investor

Yarok Microbio develops a rapid microbiological testing system for pathogen detection in fresh food products and production environments. The platform enables faster, more reliable testing with minimal training requirements, serving food producers and testing laboratories across the fresh food industry.

1 investor

Yarrow Bioscience develops a first-in-class anti-TSHR antibody to treat thyroid autoimmune diseases, specifically Graves' disease and thyroid eye disease. It operates in the biotech and therapeutics space.

1 investor

Yeastime develops ultrasound technology to optimize fermentation processes for industrial clients in brewing and bioprocessing sectors, enabling faster production cycles and reduced energy consumption. The company applies proprietary ultrasound-mediated stimulation to enhance efficiency and sustainability in fermentation operations.

1 investor

Onima is a biotechnology laboratory that upcycles brewer's yeast, a by-product of beer production, into complete, nutrient-rich food ingredients. It offers brewers a large-scale solution for repurposing waste yeast into ingredients for the human food chain.

1 investor

YISSUM is a technology transfer organization founded in 1964 that commercializes research from the Hebrew University, connecting groundbreaking academic innovations with industry partners and global markets. It operates an ecosystem supporting researchers, entrepreneurs, and industry collaborators in licensing, partnerships, and venture creation.

1 investor

Ykrita develops the EBDLR System, a bioengineered liver-assist device that supports blood purification and regeneration for patients with acute liver failure, offering an alternative to transplant surgery. The company focuses on innovative medical technologies to improve patient outcomes and make healthcare more accessible and effective.

1 investor

Y-mAbs develops radioimmunotherapy and antibody-based therapies targeting pediatric and adult cancers, with a heritage in high-risk neuroblastoma and expansion into additional oncology indications.

1 investor

YolTech Therapeutics develops in vivo gene editing medicines using a proprietary lipid nanoparticle delivery platform to treat genetic, metabolic, and autoimmune diseases. The company operates clinical-stage programs targeting conditions including Transthyretin Amyloidosis, Alpha-1 Antitrypsin Deficiency, Primary Hyperoxaluria, Beta Thalassemia/Sickle Cell Disease, and Familial Hypercholesterolemia.

1 investor

Yosemite is working toward making cancer non-lethal, focusing on cancer research and treatment.

1 investor

YouCare (悦康药业, Yisheng/YK Pharmaceutical Group) is a pharmaceutical company focused on drug research and development, including innovative drugs, traditional Chinese medicine, and nucleic acid therapeutics. It develops treatments such as inhalation formulations and has pursued clinical trial approvals in China and the US.

1 investor

YoungHeartValve develops a tissue-free transcatheter aortic valve replacement (TAVR) technology that integrates hyaluronan into synthetic polymer leaflets to resist thrombosis and calcification. Its fully synthetic, animal-free valve platform is designed for automated, scalable manufacturing and multiple valve indications in the structural heart intervention field.

1 investor

Yseop provides an AI-powered platform that automates medical writing and regulatory reporting tasks for life sciences teams, accelerating document submission timelines within the CTD pyramid framework. The platform uses neuro-symbolic AI to transform complex documentation workflows and ensure compliance in pharmaceutical regulatory processes.

1 investor

Yunu offers a clinical trial imaging platform that harmonizes imaging workflows, data, and compliance from initial scan through trial submission, cutting turnaround times and reducing manual work. It serves sponsors, CROs, and cancer centers running oncology and other clinical trials, aligning radiology, oncology, and trial roles in a single system.

1 investor

Wuhan YZY Biopharma is a biotechnology company developing bispecific antibody (BsAb) therapies to treat cancer, cancer-related complications, and age-related ophthalmic diseases. It also develops preventive and therapeutic vaccines, including Y2019, a recombinant SARS-CoV-2 subunit protein vaccine developed with the Wuhan Institute of Virology.

1 investor

Z-Alpha is a biotech developing targeted alpha-emitting radiotherapeutics based on a proprietary astatine-211 (211At) platform, including isotope supply, labeling/linker technologies, and a pipeline of therapeutic programs. It targets high unmet medical needs across multiple large-market oncology indications.

1 investor

Zafer Therapeutics develops an allogeneic, off-the-shelf cell therapy platform that programs naive mesenchymal stromal cells (MSCs) in disease-mimicking environments to create targeted anti-inflammatory treatments for systemic autoimmune rheumatic diseases. Its lead candidate, HXB-319, is aimed initially at ANCA-associated vasculitis.

1 investor

Zalvac develops innovative vaccines against bacterial infections using bacterial membrane vesicles as a platform, targeting pathogens like Streptococcus pneumoniae. The company is founded by leading microbiology researchers at Karolinska Institutet.

1 investor

Zavia Bio develops engineered proteins and peptides that act as biostimulants and biocontrol agents to help crops tolerate heat, drought, and other climate-related stress while reducing agrochemical use. It uses a proprietary platform combining bioinformatics, AI, and synthetic biology, with products including the Z-Active biostimulant and biocontrol agents in development.

1 investor